EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD
Globe Newswire•19/10/2026•07:00 ET
0
Key Highlights
- ➤LUCIA missed statistical non-inferiority on mean BCVA change versus aflibercept control
- ➤LUCIA cut treatment burden 38%, with 52% of eyes supplement-free through Week 56
- ➤DURAVYU maintained a favorable safety profile with redosing in LUCIA
- ➤COMO and CAPRI Phase 3 DME topline data remain expected in Q4 2027
Expert Statements
Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint
“We are disappointed that the LUCIA trial did not meet the primary endpoint given the promising scientific rationale of DURAVYU and its potential to improve outcomes for patients with wet AMD. We sincerely thank the patients, caregivers, clinicians and study teams who participated.”
Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint
“Both LUCIA and LUGANO demonstrated DURAVYU’s ability to control fluid and reduce the treatment burden for patients with wet AMD. These findings support DURAVYU’s therapeutic potential in DME. With the multifactorial and inflammatory nature of DME, as well as compelling results in the Phase 2 VERONA trial, we believe DURAVYU is well positioned to potentially deliver stable vision with fewer injections than standard of care. We remain focused on executing on our Phase 3 DME program and continue to be guided by our unwavering mission of serving the retinal disease community.”
Ramiro Ribeiro, M.D., Ph.D., Chief Medical Officer of EyePoint
“We are encouraged that more than 50% of DURAVYU patients remained supplement-free up to 56 weeks in both Phase 3 trials, providing further evidence of DURAVYU’s durability in retinal disease. We remain confident in the DME program, supported by DURAVYU’s biologic activity through inhibition of VEGF and the IL-6/JAK1 pathway, its continued favorable safety profile, and the early visual and anatomic improvements observed in VERONA.”
– LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement –
– Key secondary endpoints in LUCIA were met including a superior 38% reduction in treatment burden (nominal p-value <0.0001), with 52% of eyes supplement-free and 71% receiving zero or one supplement up to Week 56, as well as strong anatomic control –
Get started
Create a free account to read the full story.